In ISOS we propose to develop the first biomedical product for the in-situ fabrication and auto-renewed delivery of therapeutic compounds employing large ecosystems of probiotic genetically engineered bacteria (GEB) integrated in a biomaterial-based bioreactor.
This project is funded by the European Union’s EIC-Pathfinder Programme, under the Grant Agreement number 101130454
ISOS presents a visionary approach to in situ fabrication and auto-renewed delivery of therapeutic compounds.
ISOS aims to seamlessly integrate genetically engineered bacteria into a biomaterial-based bioreactor.
ISOS targets the wet form of age-related macular degeneration, proposing a genetically engineered bacteria bioreactor to replace frequent injections against vascular endothelial growth factor.
This initiative holds the promise of transforming prolonged treatments into personalised, efficient and minimally invasive healthcare experiences.
Miroslava from Alien attended the 10th EU-Startups Summit that took place in Malta on May 9-10.
